Smith Thornton Advisors’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
Other funds holding NVO
Smith Thornton Advisors's NVO Position: Q3 2026 in Review
Smith Thornton Advisors sold out of Novo Nordisk (NVO) in Q3 2026, closing a stake of 4,615 shares — an estimated $227K sold.
Smith Thornton Advisors first reported a position in NVO in Q2 2024 and held it in 2 quarters. The position peaked at $227K in Q2 2026. 1,237 funds tracked by Wall St. Rank hold NVO as of Q3 2026.
- Smith Thornton Advisors reported no remaining Novo Nordisk position as of Q3 2026 after selling out during the quarter.
- Smith Thornton Advisors sold 4,615 Novo Nordisk shares in Q3 2026, an estimated $227K.
- Smith Thornton Advisors first reported a position in Novo Nordisk in Q2 2024 and held it in 2 quarters.
- Smith Thornton Advisors's Novo Nordisk position peaked at $227K in Q2 2026.
- 1,237 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.
Based on Smith Thornton Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.